echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui Pharmaceuticals ERK Inhibitor Approved for Clinical

    Hengrui Pharmaceuticals ERK Inhibitor Approved for Clinical

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 26, the CDE official website showed that Hengrui's application for clinical trial of extracellular regulatory protein kinase (ERK) inhibitors has been approved by the State Food and Drug Administration by default.


    The MAPK signaling pathway is transmitted to multiple targets in the cell via RAS-RAF-MEK-ERK.


    Previously, BPI-27336 from Betta Pharmaceuticals, HH2710 jointly developed by the Chinese Academy of Sciences and Shanghai Haihe, and Hutchison Whampoa's HMPL-295S1 were approved for clinical use.


    PharmaGo

    In addition, Deck Pharmaceuticals reached a global exclusive license agreement with AstraZeneca in November 2019, and obtained the right to jointly develop and commercialize the ERK1/2 inhibitor AZD0364 (ATG-017).


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.